Document is current
Any future updates will be listed below
-
Authors
Kung, Heng-Chung
Zheng, Kevin W.
Zimmerman, Jacquelyn W.
Zheng, Lei https://orcid.org/0000-0003-4163-2541
- License Information
-
More Information
Article History
Accepted: 9 September 2025
First Online: 3 October 2025
Change Date: 13 October 2025
Change Type: Update
Change Details: In the version of the article initially published, the name of peer reviewer P. Phillips appeared incorrectly (as Philips) and has now been corrected in the HTML and PDF versions of the article.
Competing interests
: L.Z. has acted as a consultant and/or adviser of Akrevia/Xilio, Alphamab, Amberstone, Ambrx Biosion, Clinicaltrial Option, Duo Oncology, Fortress Biotech, Histosonics, Mingruizhiyao, NovaRock, QED and Tavotek, has received research funding from Abmeta, AstraZeneca, Bristol-Meyer Squibb and Merck and holds shares in Alphamab, Amberstone, Cellaration and Mingruizhiyao. J.W.Z. has received research funding from Roche Genentech. The other authors declare no competing interests.
